The therapeutic effectiveness of cancer therapy often relies on induction of apoptotic cell death. Gene -therapy -mediated induction of apoptosis, therefore, may provide an effective means to kill cancer cells. The N5 gene encodes a death -domain -containing protein ( p84N5 ) that can trigger atypical apoptosis from within the nucleus, suggesting it may be a candidate for use as a gene therapy for cancer. In the present study, we test the potential utility of a recombinant adenovirus designed to express the N5 gene ( AdN5 ) for the treatment of a variety of human cancers using in vitro and animal models. In vitro, adenoviral -mediated N5 gene transfer inhibits the growth of five different tumor cell lines, but not a normal diploid fibroblast cell line. Adenoviral -mediated N5 gene transfer also reduces the growth and metastasis of primary human tumors in subcutaneous and orthotopic xenograft mouse models. Reduction in tumor cell growth in vitro and in vivo correlates with increased expression of p84N5 and induction of apoptosis. The relative sensitivity of different human cancer cells to AdN5 or Adp53 varies, suggesting that AdN5 may be effective in tumors relatively resistant to p53 gene therapy. We conclude that N5 has potential utility for the gene therapy of cancer.
C
ancer is a result of defects in the coordination of cell proliferation and programmed cell death. The extent of cell death is physiologically controlled by activation of a programmed suicide pathway that results in a morphologically recognizable form of death termed apoptosis. 1, 2 The therapeutic effectiveness of many cancer therapies relies on the specific induction of apoptotic cell death in tumor cells. Gene -therapy -mediated induction of apoptosis or restoration of apoptotic sensitivity may provide effective means to treat cancer, 3 particularly cancers that are notoriously resistant to traditional forms of therapy. 4, 5 This principle has been validated using genes that are known to regulate apoptosis. For example, adenoviral -mediated p53 gene therapy has been demonstrated to suppress the growth of human pancreatic cancer cells by induction of apoptosis. 6 However, transduction of the p53 gene does not effectively inhibit the growth or increase chemosensitivity of all pancreatic cancer cell lines that have been tested, 7 suggesting that p53 gene therapy alone may not consistently produce beneficial therapeutic effects. By analogy to combination chemotherapeutic regimens, combination gene therapy using genes that activate different apoptotic pathways are likely to improve therapeutic response and reduce the likelihood of resistance and recurrence. A prerequisite for effective combination gene therapy, therefore, is the identification of additional genes that regulate a variety of distinct apoptotic pathways.
The N5 gene has been cloned based on the ability of its encoded protein to bind an amino terminal domain of the Rb gene. 8 N5 protein contains sequence similarity to the death domains of other proteins involved in the regulation of apoptosis. 9 Indeed, expression of N5 protein ( p84N5 ) induces apoptosis that is associated with caspase activation, NF -B activation, changes in Bcl -2 family protein levels, and activation of cell cycle checkpoints. 10, 11 The pattern of N5 -induced caspase activation, NF -kB activation, Bcl -2 family protein level alterations, and cell cycle checkpoint activation suggests it triggers an apoptotic pathway distinct from that triggered by p53. Apoptosis induced by expression of p84N5 is dependent on an intact death domain and is inhibited by coexpression of Rb. 12 In many human cancers like retinoblastoma, small -cell lung carcinoma, and bladder carcinoma Rb is lost through gene mutation. Although the wild -type Rb gene is present in many other human cancers, protein function is often deregulated by alternative mechanisms. For example, the great majority of cervical carcinomas express the human papillomavirus (HPV ) E7 oncoprotein that binds to Rb protein and inactivates its function. 13 -15 Many other cancers exhibit increased levels of an Rb regulatory kinase or decreased levels of Rb kinase inhibitors. These alterations cause deregulated Rb protein phosphorylation and inactivation of its tumor suppressor function. 16 -18 It has been suggested that compromising the Rb growth control pathway is a prerequisite for all human cancer. 19 These observations suggest that N5 -based gene therapy may induce cell death preferentially in tumor cells relative to surrounding normal cells.
These observations suggest rationale for using N5 as a gene therapy for cancer. First, N5 contains a functional death domain and may be expected to efficiently trigger apoptotic cell death. Second, N5 may trigger a novel apoptotic pathway that may kill tumor cells relatively resistant to other apoptotic regulatory genes like p53. Third, Rb inhibits N5 -induced apoptosis suggesting that normal cells may be resistant to N5 gene therapy relative to tumor cells in which Rb protein is deregulated. In the present study, we attempt to verify the validity of these rationales. We compare the effects of adenovirus -mediated N5 gene therapy in tumor cells and normal cells. We also investigate whether N5 gene therapy can effectively suppress tumor growth and metastasis in subcutaneous and orthotopic mouse models of human cancer. Finally, we compare the effectiveness of N5 and p53gene therapy.
Materials and methods

Cell culture and animal models
The FG human pancreatic adenocarcinoma cell line was originally established from COLO 357 human pancreatic carcinoma cells and is metastatic in nude mice. 20 Rb protein is expressed normally in COLO 357. 37 Although the status of p16Ink4 in COLO 357 has not been described, nearly all pancreatic adenocarcinomas that have been tested lack normal p16 expression. 38 The SK -OV3 (Rb positive, p16 null ) 39 ovarian carcinoma cell line, the SAOS -2 (Rb negative) 40 and U2OS (Rb positive, low p16 ) 41 osteosarcoma cell lines, the MDA -MB -453 (Rb positive, 42 cyclin D1 amplification 43 ) breast carcinoma cell line, the WI38 normal human fibroblast cell line, and the 293 cell line were obtained from American Type Culture Collection. All of the cell lines express p84N5 detectable by Western blot analysis ( data not shown), although the relative level of expression varies by as much as 5 -fold from high -expressing lines (U2OS) to lowexpressing lines (WI38 ). All cells were maintained in Dulbecco's modified Eagle's medium with 10% fetal bovine sera and antibiotics (100 U /mL penicillin, 100 g/mL streptomycin ), in a 5% CO 2 incubator at 378C. Male athymic BALB/ c nude mice were purchased from the Animal Production Area of the National Cancer Institute, Frederick Cancer Research Facility (Frederick, MD ). The mice were housed in laminar flow cabinets under specific pathogen -free conditions. Animals were maintained in facilities approved by the American Association for Accreditation of laboratory Animal Care in accordance with current regulations and standards of the U.S. Department of Agriculture, Department of Health and Human Services and NIH.
For the subcutaneous mouse model, exponentially growing SKOV3 -IP1 or FG cells were harvested after a brief exposure to trypsin, then washed and resuspended in phosphatebuffered saline ( PBS ). A total of 5Â10 5 SKOV3-IP1 or Colo357.X cells were injected subcutaneously into nude mice. Once tumor volumes reached 40 -50 mm 3 , 100 l of adenovirus suspension (1.0Â10 8 pfu ) was injected intratumorally weekly for 3 weeks. PBS was used as a vehicle for sham control. Tumor diameters in three dimensions were measured weekly using a caliper and estimates of tumor volume were calculated from these measurements.
For orthotopic tumor growth, nude mice were anesthetized with methoxyflurane and placed in the supine position. An upper midline abdominal incision was made, and the pancreas was exteriorized. A total of 1Â10 6 FG cells prepared as above in 50 l Hepes -buffered saline solution (HBSS ) were injected into the tail of the pancreas ( n= 10 for each treatment ). Adenovirus (1.0Â10 8 pfu in 50 l) was intratumorally injected on day 14 and 20 post tumor implantation. At the time of adenovirus infection, tumors were typically 4 mm in diameter. Only mice containing tumors with a diameter of 3 -5 mm were used and were randomly selected for treatment. Mice were killed on day 60 or when moribund. Tumors were collected and weighed, and liver metastases were counted with the aid of a dissecting microscope.
Preparation of recombinant adenovirus
The construction of the E1 -deleted, replication defective adenovirus designed to express p84N5 (AdN5 ) or the green fluorescent protein ( AdGFP ) were described previously. 21 Large -scale viral preps were harvested from 293 cells at 36-40 hours postinfection by resuspension in PBS and lysis by freeze -thaw. Virus was purified from cleared lysate by CsCl equilibrium density gradient centrifugation, and viral particles were quantitated by spectrophotometry as described previously. 22 The recombinant adenovirus engineered to express p53 was constructed similarly, 23 and purified viral stocks were purchased from the M. D. Anderson Vector Core Laboratory. Infectious titer was estimated by an endpoint plaque assay on 293 cells. The concentrated virus was dialyzed against PBS plus 10% glycerol, aliquoted, and stored at À 808C.
Analysis of infected tumor cells
To measure the effect of viral infection on cell growth, cells were plated at a density of 20,000 cells /well in 12 -well plates in triplicate. Cells were infected with AdN5, AdGFP, or PBS as above. The following day, media was changed to remove the viral supernatant. Cells were harvested at indicated time intervals and viable cells counted using trypan blue and a hemacytometer. In vitro infected cells were analyzed for DNA fragmentation and protein expression as described. 21 Subcutaneous tumors were resected and sectioned for immunohistochemical analysis of p84N5 expression and apoptosis by terminal deoxytransferase labeling of fragmented DNA as described. 24 For both Western blotting and immunohistochemical analysis, the p84N5 8 antibody was used at a dilution of 1:1000.
Results
Sensitivity to adenoviral -mediated gene transfer
Five human tumor cell lines and one normal human cell line were used to study the effects of AdN5 infection in vitro and in vivo. The five human tumor cell lines were derived from ovarian carcinoma (SKOV3-IP1 ), osteosarcoma (SAOS -2 and U2OS ), breast carcinoma (MDA -MB -453), and pancreatic adenocarcinoma ( FG, a fast -growing variant of COLO 357). The WI38 human diploid fibroblast cell line was used to model normal human cells. We compared the sensitivity of these cell lines to adenoviral -mediated gene transduction by infecting them at a known multiplicity of infection (MOI) with AdGFP and measuring the percentage of cells fluorescing green the following day. At an MOI of 10, SAOS -2, USOS, MDA -MB -453, and WI38 cells exhibited greater than 90% green fluorescent cells. An MOI of 10 was used for all subsequent in vitro experiments with these lines. SKOV3 -IP1 and FG cells required an MOI of 50 to exhibit greater than 90% green fluorescent cells. An MOI of 50 was used for all subsequent in vitro experiments involving these two cell lines.
N5 gene transfer inhibits cell proliferation in vitro by induction of apoptosis
To determine the effect of AdN5 infection on the proliferation of FG cells in vitro, growth curves were measured after treatment with AdN5, Adp53, AdGFP, or PBS. Infection with AdN5 or p53 inhibited cell proliferation relative to treatment with AdGFP or PBS (Fig 1A ) . Significantly fewer viable cells accumulated in AdN5 or Adp53 infected cultures as early as day 3 postinfection and cell numbers declined after day 5. Inhibition of tumor cell growth by AdN5 was at least as great as with Adp53. Treatment of cells with AdGFP had no detectable affect on cell proliferation relative to PBS treated cells.
To ensure that the decrease in proliferation of AdN5 infected cells was due to successful N5 gene transfer, we analyzed similarly infected cultures of FG cells for p84N5 by Western blotting. An increase in p84N5 expression was observed as early as 12 hours after infection in AdN5 infected cells relative to AdGFP infected cells ( Fig 1B ) . Levels of p84N5 increase 2-to 3 -fold upon AdN5 infection and the increase persists until at least 40 hours postinfection. The modest increase in p84N5 levels upon infection with AdN5 is probably due to the observation that full -length p84N5 decreases during apoptosis presumably due to protein degradation. 12 To test the hypothesis that the decrease in viable cells subsequent to AdN5 infection was mediated by induction of apoptosis, we analyzed infected cells for the presence of regularly fragmented DNA, a hallmark of apoptotic cells. Regularly fragmented DNA was detected in AdN5 -infected cells, as indicated by the appearance of DNA ladders, but not in AdGFP -infected or PBS -treated cells (Fig 1C ) .
Tumor cells are more sensitive to the effects of AdN5 than normal cells
Since we previously demonstrated that Rb could inhibit N5 -induced apoptosis, we tested the possibility that normal cells were more resistant to the effects of N5 expression than tumor cells with deregulated Rb. The percentage of viable cells in cultures from each of five different tumor cell lines infected with AdN5 declined from greater than 90% at the time of infection to 20% or less 5 days later (Fig 2A ) . Viable cells are still detected on day 5 postinfection yet less than 5% of cells in infected cultures will survive and proliferate (data not shown). Hence, the rate of cell death in individual cells is variable. All of the tumor cell lines tested here are deregulated for the Rb growth control pathway by either Rb mutation (SAOS-2), loss of p16 expression ( U2OS, FG, SK -OV3 ), or increased cyclin D1 expression ( MDA -MB - 
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. We do not observe any obvious correlation between the molecular mechanism of Rb deregulation and sensitivity to AdN5.
In contrast to the tumor cell lines tested, the normal human fibroblast cell line WI38 with intact Rb -mediated growth control is resistant to AdN5. The percentage of viable WI38 cells infected with AdN5 was 90% or greater throughout the course of the experiment. Not only were WI38 cells less sensitive to AdN5 -induced cell death, but they were also resistant to N5 -induced cell cycle arrest because the growth rate of AdN5 and AdGFP infected cells was similar ( Fig 2B ) . The difference in AdN5 sensitivity between the tumor and normal cell lines was not due to differences in the efficiency of adenoviral -mediated gene transfer because the MOI used to infect each cell line was adjusted to ensure that greater than 90% of the cells were infected.
To address the possibility that differences in sensitivity were due to differences in the levels of p84N5 expressed Cancer Gene Therapy N5 gene therapy of pancreatic carcinoma S Yin et al upon successful infection, we compared p84N5 levels 2 days after infection in sensitive FG tumor cells and insensitive WI38 normal cells. Both endogenous and induced levels of p84N5 were higher in the FG cell line compared to WI38 ( Fig 2C ) . The significance of this variation in endogenous p84N5 levels is unknown. However, densitometric comparison of the AdGFP and AdN5 infected samples indicated that the relative increase in p84N5 levels upon AdN5 infection was similar for each cell line. In FG cells, AdN5 infection led to a 2.9 -fold increase in p84N5 signal whereas a 3.1 -fold increase was observed in WI38 cells.
N5 gene transfer inhibits ectopic growth of human ovarian and pancreatic cancer in mice
To test the potential utility of N5 gene therapy in the treatment of pancreatic or ovarian cancer, we first tested the effects of AdN5 infection in subcutaneous mouse models using FG or SKOV3 -IP1 cells. Viable cells were subcutaneously injected into the flanks of nude mice and tumors allowed to grow for 1 -2 weeks until they reached a palpable size. Tumors were then treated by three weekly intratumoral injections of AdN5, Adp53, or AdGFP. Tumor volume was monitored weekly for 5 weeks. The size of both FG and SKOV3 -IP1 tumors was significantly reduced upon treatment with AdN5 relative to those tumors treated with AdGFP (Fig 3) . For SKOV3 -IP1 tumors, Adp53 and AdN5 had similar effect in preventing tumor growth. Although both Adp53 and AdN5 slowed the growth of FG tumors by a statistically significant margin, the AdN5 -treated tumors were 4 -fold smaller than the Adp53 -treated tumors by the end of the 5 -week experiment.
To ensure that the reduction in tumor growth upon AdN5 treatment was due to induction of apoptosis subsequent to successful N5 gene transfer, FG tumors were harvested and tumor sections analyzed for expression of p84N5 by immunohistochemistry and for apoptosis by TUNEL assay. In contrast to AdGFP -treated tumors that express low levels of endogenous p84N5, a significant fraction of AdN5 -infected tumor cells exhibited darkly stained nuclei with the anti-N5 antibody ( Fig 4 ) , consistent with increased p84N5 expression and successful gene transfer. In contrast to AdGFP -treated tumors that exhibited few if any TUNELpositive cells, apoptotic cells were frequently detected in sections of tumors treated with AdN5 as determined by TUNEL -stained nuclei and apoptotic cellular morphology.
N5 gene transfer inhibits orthotopic growth and metastasis of human pancreatic cancer in mice
To assess the effects of N5 gene therapy on the growth and metastasis of primary pancreatic tumors under more physiological conditions, we tested the effects of AdN5 treatment in an orthotopic model of pancreatic adenocarcinoma. 25, 26 Beginning 2 weeks after implantation of FG cells into the pancreas of nude mice, tumors were treated with AdN5, AdGFP, or PBS. The mice were sacrificed on day 60 postimplantation, or when moribund, and the mass of the primary tumors was measured. AdN5 treatment reduced the mass of the resulting primary tumors by at least 2 -fold relative to PBS or AdGFP -treated tumors ( Table 1) . The difference between AdGFP -and AdN5 -treated tumors was statistically significant with a P value of less than .01 by Student t test. In addition, we measured the incidence and number of liver metastasis in these mice. AdN5 reduced both the incidence and mean number of liver metastasis. Again, the difference between AdGFP -and AdN5-treated tumors was statistically significant with a P value of less than .01 by Kruskal -Willis U test.
Discussion
We demonstrate in this study that adenovirus -mediated N5 gene transfer can inhibit the proliferation of tumor cells in vitro and in vivo. This conclusion is based on the significant reduction in tumor cell growth rate in vitro and the reduction in tumor volume or mass in vivo that is observed upon AdN5
Anti-N5(10X) Anti-N5(40X) TUNEL AdGFP AdN5 Figure 4 Inhibition of tumor growth in vivo by AdN5 treatment is coincident with p84N5 overexpression and induction of apoptosis. Subcutaneous FG tumors were harvested 2 days following intratumoral injection of AdGFP ( top row of panels ) or AdN5 ( bottom row of panels ). Sections were analyzed for p84N5 expression by immunohistocytochemistry ( left four panels ) or for fragmented DNA by TUNEL ( right two panels ). Representative sections were photographed using either a 10Â or 40Â objective, as indicated, for immunohistocytochemistry or a 40Â objective for TUNEL staining. and subsequent apoptosis. 10 Consistent with this notion AdN5 infection increases the percentage of apoptotic cells within tumor cells growing in vitro or in vivo as measured by detection of fragmented DNA and cellular morphology. This study and our previous work indicate that AdN5 similarly affects a number of different tumor cell lines of different tissue origin, including breast, ovarian, and pancreatic carcinoma as well as osteosarcoma and embryonal carcinoma. Hence, the effects of AdN5 are unlikely to be specific for a particular tumor type.
We also provide evidence that tumor cells are more sensitive to the effects of AdN5 than normal fibroblasts. The loss in cell viability observed subsequent to AdN5 infection in each of the five tumor cell lines tested was not observed in the normal, diploid fibroblast cell line WI38. WI38 cells were also resistant to the cell cycle effects of AdN5 because the growth rate of AdGFP, AdN5, and mock -infected cells were similar. The difference between the tumor and normal cell lines was not due to differences in the extent of successful gene transfer or the extent of p84N5 induction. In each of the tumor or normal cell lines tested, the levels of p84N5 increased approximately 3 -fold upon AdN5 infection. Further work will be required to test the hypothesis that the resistance of normal cells to AdN5 is mediated by the presence of a functional Rb growth control pathway.
Treating cancer by p53 gene therapy has received attention because preclinical and phase I clinical trials have yielded promising therapeutic effects in a number of cancers. 27 -31 Like N5, p53 gene therapy limits tumor cell growth by induction of cell cycle checkpoints and apoptotic cell death. However, some tumor cells are insensitive to p53 gene therapy, particularly those that express wild -type p53 or overexpress mdm2. 32 -34 Hence, the effectiveness of p53 gene therapy may be dependent on the status of the p53 regulatory pathway within individual tumors. The mechanism of N5 -induced cell death is uncharacterized. However, several observations indicate that AdN5 activates an apoptotic pathway that is distinct from that activated by Adp53. 35, 36 For example, Adp53 infection induces a G1 cell cycle arrest and subsequent apoptosis 33 whereas AdN5 causes a G2 / M cell cycle arrest followed by apoptosis.
11
AdN5 treatment activates NF -B, 10 whereas p53 inhibits its activation. Although N5 contains sequence similarity to other death -domain -containing proteins that induce apoptosis, it is likely to function differently because it is localized exclusively within the nucleus during interphase. We show here that FG pancreatic tumor cells are more sensitive to AdN5 than they are to Adp53 based on the significantly smaller tumors remaining after treatment with AdN5 compared to Adp53. We conclude that N5 gene therapy may be effective in tumors that are relatively insensitive to p53 gene therapy. The relative sensitivity of tumor cells to N5 or p53 gene therapy varies, however. Whereas AdN5 is more effective in treating FG cell tumors, Adp53 and AdN5 are equally effective in treating SKOV3 -IP1 tumors. Again, differences in the relative response of different tumor cells to AdN5 or Adp53 are not due to differences in adenoviralmediated gene transfer because FG and SKOV3-IP1 cells express similar levels of p84N5 after AdN5 infection ( Yin, unpublished ) . Because the relative response to AdN5 and Adp53 varies, it is possible that tumor specifically resistant to AdN5 may be discovered. One approach to overcoming this limitation to cancer gene therapy is the simultaneous use of multiple genes that trigger distinct cytostatic or cytotoxic pathways. Interestingly, the use of AdN5 and Adp53 together inhibits tumor growth better than either virus alone at the same total virus dose (Yin et al, unpublished ) . Whereas this has not been verified in vivo, it suggests that simultaneous use of different genes may overcome the resistance a tumor may have for treatment with one particular gene. A variation on this approach would be to use a specific gene therapy in conjunction with other traditional therapies in the hopes that the gene therapy may restore sensitivity to traditional therapy or vice versa. Consistent with this hypothesis, we have observed that the levels of endogenous p84N5 in a subset of tumor cell lines ( n= 6 ) correlate with sensitivity to ionizing radiation (Goodrich et al, unpublished). The higher the level of endogenous p84N5, the more sensitive the tumor cells are to radiation, suggesting that N5 gene therapy may restore sensitivity to genotoxic agents in tumor cells. Further work is required to verify this possibility.
Based on the known molecular properties of the N5 gene and its encoded protein, we proposed a rationale for using N5 as a gene therapy for cancer. First, because expression of N5 is known to trigger an atypical cell cycle checkpoint and apoptotic response, it may be effective in treating tumors that are resistant to gene therapies that activate other apoptotic pathways. Second, by analogy to other deathdomain -containing proteins N5 would be expected to efficiently trigger an apoptotic response thus providing the basis for a favorable clinical outcome. Third, N5 protein associates with Rb protein and this association inhibits N5 -induced cell death. Tumor cells with deregulated Rb protein function may be more sensitive to the effects of N5 than surrounding normal cells. The data presented here verify each of these rationale and support the use of N5 as a gene therapy for cancer.
antibody. We thank other members of the Goodrich laboratory for helpful discussions. We acknowledge Carolyn Cooke for expert technical assistance. This work was supported by the National Institutes of Health Grant CA -70292 ( D.W.G. ) and RPG -00 -054 -01 -CMS from the American Cancer Society ( K.X. ).
